Literature DB >> 14568823

Development of generalized myasthenia gravis in patients with ocular myasthenia gravis.

T H Papapetropoulos, J Ellul, E Tsibri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14568823     DOI： 10.1001/archneur.60.10.1491-b

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  4 in total

1.  Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.

Authors:  Michael Benatar; Michael P Mcdermott; Donald B Sanders; Gil I Wolfe; Richard J Barohn; Richard J Nowak; Michael Hehir; Vern Juel; Hans Katzberg; Rabi Tawil
Journal:  Muscle Nerve       Date:  2016-01-27       Impact factor: 3.217

Review 2.  Medical and surgical treatment for ocular myasthenia.

Authors:  Michael Benatar; Henry Kaminski
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

3.  Clinical predictors for the prognosis of myasthenia gravis.

Authors:  Lili Wang; Yun Zhang; Maolin He
Journal:  BMC Neurol       Date:  2017-04-19       Impact factor: 2.474

4.  Lower number of plasma exchange sessions and glomerular filtration rate decline are associated with second relapses in patients with myasthenia gravis.

Authors:  Vedran Premuzic; Ervina Bilic; Branimir Ivan Sepec; Mirea Hancevic; Hrvoje Bilic; Barbara Sitas; Rujana Sprljan Alfirev; Bojan Jelakovic
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.